The N-terminal sequence and internal sequences of the purified taro α-galactosidase (α-Gal) were determined using tandem mass spectrometry. By using reverse transcriptase PCR (RT-PCR), 5′ and 3′ rapid amplification of cDNA ends (RACE) with designed, degenerate primers, a novel cDNA sequence was obtained. The recombinant taro α-Gal not only hydrolyzes α1→4 linked galactosyl residues, which are accumulated in the tissues from patients with Fabry disease, but also hydrolyzes the α1→3 linked galactoside of B red blood cells (RBC). The recombinant taro α-Gal provides an ideal enzyme source for biomedical systems.
Biocatalysis and Agricultural Biotechnology 1(2),pp.135-139